Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
quadrivalent human papillomavirus recombinant vaccine
- Development stage
- Phase 3
- Lead developer
- Shanghai Bovax Biotechnology
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
The Bovax quadrivalent HPV vaccine is a recombinant vaccine designed to protect against Human Papillomavirus (HPV) types 6, 11, 16, and 18. Developed by Shanghai Bovax Biotechnology Co., Ltd. and its collaborator Chongqing Bovax Biopharmaceutical Co., Ltd., the vaccine is produced using a *Hansenula polymorpha* (yeast) expression system to generate virus-like particles (VLPs) of the L1 capsid protein for each targeted HPV type. It is intended for the prevention of HPV-associated diseases, including cervical cancer, genital warts, vaginal cancer, and cervical intraepithelial neoplasia (CIN1/2/3). The vaccine is currently in Phase 3 clinical development (e.g., NCT05027776), where its immunogenicity and safety are being evaluated in healthy Chinese females aged 9–26 years, specifically comparing 2-dose and 3-dose vaccination schedules.
- Other names
- 3-dosesBovax quadrivalent HPV vaccineShanghai Bovax quadrivalent HPV vaccineQuadrivalent Human Papillomavirus Recombinant Vaccine (Type 6, 11, 16, 18)
02
Targets
HPV11 L1HPV16 (Human papillomavirus type 16)HPV18 L1HPV6 L1 (Human papillomavirus type 6 major capsid protein L1)
Beyond the preview
Go deeper on quadrivalent human papillomavirus recombinant vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on quadrivalent human papillomavirus recombinant vaccine.